Ignite Creation Date:
2024-05-06 @ 12:37 AM
Last Modification Date:
2024-10-26 @ 10:52 AM
Study NCT ID:
NCT01616199
Status:
TERMINATED
Last Update Posted:
2018-05-16
First Post:
2012-06-06
Brief Title:
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Sponsor:
Cascadian Therapeutics Inc
Organization:
Seagen Inc
Organization Data
Organization:
Seagen Inc
Class:
INDUSTRY
Study ID:
PX-866-007
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cascadian Therapeutics Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None